Novartis Ag (NVSEF) Income from Continuing Operations (2009 - 2025)

Novartis Ag has disclosed Income from Continuing Operations across 15 years of filings, most recently posting 4531000000.0 for Q2 2025.

• Income from Continuing Operations for Q2 2025 came in at 4531000000.0, up 17.96% year-over-year; the trailing twelve-month figure through Jun 2025 was 20536000000.0 (up 67.94% YoY), and the FY2025 annual result was 13967000000.0, up 16.99% from the prior year.
• Income from Continuing Operations came in at 4531000000.0 for Q2 2025 at Novartis Ag, down from 6970000000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 6970000000.0 in Q4 2024 to a low of 514000000.0 in Q1 2021.
• The 5-year median for Income from Continuing Operations is 3090000000.0 (2021), against an average of 3019857142.86.
• Across the five-year window, Income from Continuing Operations surged 164.95% in 2021 and slumped 41.76% in 2022, its largest moves.
• Novartis Ag's Income from Continuing Operations stood at 5956000000.0 in 2021, then declined by 20.9% to 4711000000.0 in 2022, then rose by 10.25% to 5194000000.0 in 2023, then surged by 34.19% to 6970000000.0 in 2024, then slumped by 34.99% to 4531000000.0 in 2025.
• The last three Income from Continuing Operations figures came in at 4531000000.0 (Q2 2025), 6970000000.0 (Q4 2024), and 3841000000.0 (Q2 2024), per Business Quant data.